The effect of trastuzumab on cardiac function in patients with <scp>HER2</scp> ‐positive metastatic breast cancer and reduced baseline left ventricular ejection fraction-Reference-Cited by-同舟云学术

The effect of trastuzumab on cardiac function in patients with HER2 ‐positive metastatic breast cancer and reduced baseline left ventricular ejection fraction

Published:2022-04-27 Issue:4 Volume:151 Page:616-622
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Intl Journal of Cancer

Author:

Bouwer Nathalie I.¹²^ORCID,Steenbruggen Tessa G.³,Rier Hánah N.⁴,Kitzen Jos J. E. M.¹,Smorenburg Carolien H.³,van Bekkum Marlies L.⁵,de Jong Paul C.⁶,Drooger Jan C.⁷,Holterhues Cynthia⁸,Kofflard Marcel J. M.²,Boersma Eric⁹,Sonke Gabe S.³,Levin Mark‐David¹,Jager Agnes⁴

Affiliation:

1. Department of Internal Medicine Albert Schweitzer Hospital Dordrecht The Netherlands

2. Department of Cardiology Albert Schweitzer Hospital Dordrecht The Netherlands

3. Department of Medical Oncology The Netherlands Cancer Institute Amsterdam The Netherlands

4. Department of Medical Oncology, Erasmus MC Cancer Institute Rotterdam The Netherlands

5. Department of Medical Oncology Reinier de Graaf Hospital Delft The Netherlands

6. Department of Medical Oncology Sint Antonius Hospital Utrecht The Netherlands

7. Department of Medical Oncology, Breast Cancer Center South Holland South Ikazia Hospital Rotterdam The Netherlands

8. Department of Medical Oncology Haga Hospital The Hague The Netherlands

9. Department of Cardiology, Erasmus MC University Medical Centre Rotterdam Rotterdam The Netherlands

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.34024

Reference13 articles.

1. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer

2. Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer

3. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy

4. Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?

5. Herceptin[package insert]. San Francisco CA: Genentech Inc.